Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

A study has traced immune activity at high resolution in the first living recipient of a gene-edited pig kidney and has reported that – even after clinicians suppressed T-cell rejection – ...

Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...

Researchers highlight how exercise and dietary strategies may complement immunotherapy by improving immune function, tumour perfusion, and quality of life.

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...

Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 - Genmab A/S (Nasdaq: GMAB) ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as NAFLD, represents the most prevalent liver disorder globally, ...

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial.

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute lymphoblastic leukemia (T-ALL). This form of therapy used genome editing ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...